Qualitative or quantitative defects of alphaB-cristallin

Qualitative or quantitative defects of alphaB-crystallin (also known as CRYAB-related disorders or alpha-B crystallinopathy) refer to a group of rare genetic conditions caused by mutations in the CRYAB gene, which encodes the alphaB-crystallin protein. This small heat shock protein plays a critical role in maintaining proper protein folding and preventing protein aggregation in multiple tissues, particularly in the lens of the eye, skeletal muscle, and cardiac muscle. Defects in this protein can lead to a spectrum of clinical manifestations depending on the specific mutation involved. The clinical presentation of CRYAB-related disorders can include myofibrillar myopathy (a form of skeletal muscle disease characterized by progressive muscle weakness), dilated or restrictive cardiomyopathy, and cataracts (lens opacification). Some patients present primarily with isolated posterior polar cataracts, while others develop a more complex phenotype involving both skeletal and cardiac muscle dysfunction. Myofibrillar myopathy associated with CRYAB mutations typically manifests as progressive proximal and distal muscle weakness, sometimes accompanied by respiratory insufficiency. Cardiac involvement can be life-threatening and may include heart failure or arrhythmias. There is currently no curative treatment for CRYAB-related disorders. Management is supportive and symptom-directed, including surgical removal of cataracts when vision is significantly impaired, cardiac monitoring and treatment of cardiomyopathy with standard heart failure therapies, physical therapy and rehabilitation for muscle weakness, and respiratory support when needed. Cardiac transplantation may be considered in severe cases of cardiomyopathy. Genetic counseling is recommended for affected individuals and their families.

Common questions about Qualitative or quantitative defects of alphaB-cristallin